
About iECURE
iECURE is a Healthcare company based in Philadelphia (United States) founded in 2020. Online genetic engineering tools for drug development are provided. iECURE has raised $115 million across 2 funding rounds from investors including Orbimed, Novo Holdings and LYFE Capital. The company has 7 employees. Its chief executive, as recorded, is Joseph Truitt. iECURE offers products and services including ECUR-506. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Discovery. Its legal entity is iECURE, Inc. Its competitors include BridgeBio, Spark Therapeutics and Alnylam; 3 of its 3 listed competitors have raised funding.
Company details
iECURE was founded in 2020 in Philadelphia, United States. Operations center on biotechnology, with an online platform used for genetic engineering in drug development. In vivo gene insertion therapies are developed to address rare pediatric liver diseases, including ARCUS-mediated candidates. Focus remains on therapeutic advancements for these conditions, supported by expertise in gene therapy applications.
- Headquarters Philadelphia, United States
- Employees 7
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website iecure.com
- Social LinkedIn
- Legal Name Iecure, Inc.
- Total Equity Funding$115M (USD)
in 2 rounds
- Latest Funding Round$65M (USD), Series A
Nov 2022
- InvestorsOrbimed
& 3 more
- Employee Count7
Products & Services of iECURE
iECURE offers a comprehensive portfolio of products and services, including ECUR-506.
In vivo treatment for ornithine transcarbamylase deficiency via gene insertion
Funding Insights of iECURE
iECURE has successfully raised a total of $115M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $65 million completed in November 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $115M
- Total Rounds 2
- Last Round Series A β $65M
- First Round $50M
(Sep 2021)
- Investors Count 4
All 2 funding rounds of iECURE with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2022 | $65M | Series A | β | Novo Holdings, LYFE Capital | |
| Sep 2021 | $50M | Series A | β | Versant Ventures, Orbimed | β |
4 investors in total: 4 institutional.
Investors in iECURE
iECURE has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Orbimed, Novo Holdings and LYFE Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
LYFE Capital is recognized as a premier healthcare investment platform. | lyfecapital.com | Menlo Park, USA | ||
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999. | versantventures.com | |||
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States |
Investor details for iECURE
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of iECURE
25 people are tracked at iECURE (15 in leadership, 7 in board & advisors, 3 in team); the tracked headcount is 7.
| Name | Role | Group |
|---|---|---|
Joseph Truitt | CEO | Leadership |
Patricia Ward | Senior Director, Quality & Compliance | Leadership |
Paul Firuta | COO | Leadership |
Kimberly M. Smith | VP, Finance & Accounting | Leadership |
Alex Monteith | Chief Business Officer | Leadership |
David Garrett | CFO | Leadership |
Gabriel M. Cohn | Chief Medical Officer | Leadership |
George Diaz | VP, Therapeutic Area Lead, Urea Cycle Disorders | Leadership |
Matthew Hall | VP, Head of Clinical Operations | Leadership |
Mark J. Semanick | VP, Head of Technical Operations | Leadership |
Maryann A. Toto | VP, Head of Regulatory Affairs | Leadership |
Dave Lecher | Senior Director Of Supply Chain | Leadership |
Mike Burnham | Senior Director Manufacturing Sciences & Technology Lead | Leadership |
Karen Kuhn | Sr. Director Clinical Operations | Leadership |
John Blackwell | VP Quality And Compliance | Leadership |
Brian Di Donato | Director | Board & advisors |
Ray Camahort | Director | Board & advisors |
Tal Zaks | Director | Board & advisors |
James M. Wilson | Chief Scientific Advisor | Board & advisors |
Tom Woiwode | Chair | Board & advisors |
5 more people are available in the full profile.
Complete people profiles for iECURE
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of iECURE
3 dated milestones of iECURE across 2 years, from founding to its latest funding, stage changes and deals.
- Founded iECURE is founded.
- Funding First funding round of $50.0M.
- Funding Latest funding round, Series A, of $65.0M.
Competitors of iECURE
iECURE has 3 listed competitors in our database, 3 of them funded. They include BridgeBio, Spark Therapeutics and Alnylam.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. |
Detailed competitors of iECURE
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of iECURE
The website of iECURE (iecure.com) receives about 3.7K visits a month.
- Monthly visits3.7K
▲ 26% vs previous month
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as iECURE (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Iecure
Complete news archive for iECURE
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about iECURE
iECURE was founded in 2020 and raised its 1st funding round 1 year after it was founded.
iECURE is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.
Joseph Truitt is the CEO of iECURE, as recorded in our data.
iECURE is a funded company, having raised a total of $115M across 2 funding rounds to date. The company's 1st funding round was a Series A of $50M, raised on Sep 2021.
iECURE has 7 employees.
iECURE was founded in 2020 in Philadelphia, United States. Operations center on biotechnology, with an online platform used for genetic engineering in drug development. In vivo gene insertion therapies are developed to address rare pediatric liver diseases, including ARCUS-mediated candidates. Focus remains on therapeutic advancements for these conditions, supported by expertise in gene therapy applications.
iECURE's top competitors include Spark Therapeutics, BridgeBio and Alnylam.
iECURE offers ECUR-506.
iECURE has 4 investors. Key investors include Orbimed, Novo Holdings, LYFE Capital, and Versant Ventures.
iECURE operates through Iecure, Inc..
